Successful Re-administration of Atezolizumab for a Non-small-cell Lung Cancer Patient after Cardiac Tamponade Development as a Manifestation of Pseudo-progression Induced by Combination Treatment with Atezolizumab and Cytotoxic Chemotherapy

Koki Nakashima; Yoshiki Demura; Masayuki Sato; Yuya Fujii; Kazunari Igarashi; Tamotsu Ishizuka

doi:10.2169/internalmedicine.6509-20

This article has now been updated. Please use the final version.

Successful Re-administration of Atezolizumab for a Non-small-cell Lung Cancer Patient after Cardiac Tamponade Development as a Manifestation of Pseudo-progression Induced by Combination Treatment with Atezolizumab and Cytotoxic Chemotherapy

Koki Nakashima, Yoshiki Demura, Masayuki Sato, Yuya Fujii, Kazunari Igarashi, Tamotsu Ishizuka

Author information

Keywords: immune checkpoint inhibitor, lung cancer, atezolizumab, cardiac tamponade, malignant pericardial effusion, pericardiocentesis

JOURNAL OPEN ACCESS Advance online publication

Article ID: 6509-20

DOI https://doi.org/10.2169/internalmedicine.6509-20

The final version of this article is now available: Vol. 60 (2021), No. 18 pp. 3009-3013

Details

Abstract

Pseudo-progression is a phenomenon induced by treatment with immune checkpoint inhibitors and is characterized by an increase in tumor size or the appearance of new lesions, followed by tumor regression. However, life-threatening conditions, such as cardiac tamponade, can develop in such patients.

We herein report on a 69-year-old man with lung adenocarcinoma who developed cardiac tamponade as a manifestation of pseudo-progression induced by treatment with atezolizumab combined with cytotoxic chemotherapy. After managing the cardiac tamponade, atezolizumab was successfully re-administered along with cytotoxic chemotherapy without disease progression.

Corresponding author

Register with J-STAGE for free!